Why couldn't the CEO be more positive about Zertane or at least more understanding of what investors need to hear especially if ampe is shopping for a partner, Dosen`t make any sense what they said at the conference and aren't the zertane trials taking place outside the US and looking for European approval only at this point ?
I thought it was funny when you wrote in a previous post "I have done more due diligence on this company then even the analyst at Aegis", especially when you now write "My understanding is that the final phase III trial has already been completed and that they are only waiting for the FDA's response. I believe these trials took place in the U.S. recently."
Do you understand that all clinical studies in the US as listed on the FDA clin trials dot gov site? Are any of AMPE's studies listed there? Hmmmmm.
Did you eve read AMPE's June 21 press release, which said "The FDA provided all the necessary guidance on the design and conduct of two concurrent phase III pivotal clinical trials of approximately 15 weeks duration."? Do you think AMPE just snuck those in?
Also, AMPE stated in the December investor presentation for Zertane "two concurrent
Phase III pivotal trials set to begin enrollment in 1Q13". Did you miss this?
All the Zertane trials to date were done in Europe. The FDA did not accept the European trials for approval in the USA. Ampio has applied for a phase III trial in the US and are awaiting approval of that trial. My take on the CEO's remarks about Zertane is that they have a partner that will take Zertane through US Phase III once the trial is approved